Independent. No tobacco money. No corporate fluff.SUN, OCT 18

PouchDaily

The daily pulse of the nicotine pouch market

Regulation
US

FDA wants to replace the rule that decides which nicotine pouches get approved

FDA announced on September 28 it may replace the 2021 PMTA framework entirely — and its director says the nicotine pouch pilot is the model for what comes next.

PouchDaily Desk·
FDAPMTAregulationUnited Statespremarket authorizationCTP

The FDA is planning to replace the rule that governs how every nicotine pouch, vape and tobacco product gets approved in the United States. In a September 28 announcement, the agency said it intends to "evaluate changes to the PMTA regulatory framework, including through initiation of new rulemaking to replace the current framework."

That is not a tweak. The 2021 PMTA rule defines what manufacturers must submit and how the FDA weighs the evidence behind every marketing decision. Replacing it would reshape the path for the whole category — and the FDA's own nicotine pouch pilot is the model it wants to build on.

What the FDA actually said

The agency cited four drivers: its experience implementing the 2021 rule, the growth of what it calls an "illicit and unregulated market," the pace of new product introductions, and recent judicial developments — specifically a federal lawsuit in the Northern District of Texas challenging the current framework.

Nothing changes for now. The current rule stays in effect, the FDA keeps accepting and reviewing PMTAs, and any replacement would go through normal rulemaking with an opportunity for public comment. The announcement gave no specific changes and no timetable.

Why it matters for nicotine pouches

FDA's Center for Tobacco Products director Bret Koplow put real numbers on the reform push at the Food and Drug Law Institute's tobacco conference in Washington on October 6:

  • CTP has only nine scientific review teams handling PMTAs, and a new application can't enter substantive review until a team frees up. Koplow said he wants to "more than double" that number — but says other FDA centers can use the flexible Title 21 pay system and CTP can't, which would take congressional action to fix.
  • The nicotine pouch pilot worked. Twenty-three products have been authorized through the category-specific pilot, out of 43 pouch products authorized overall per FDA's August 21 update. Koplow called pouches a relatively homogeneous category where "one size doesn't necessarily fit all," and said pilot reviews finished in record time without lowered standards.
  • A supplemental PMTA (sPMTA) pilot is in development for modifications to already-authorized products — things like ingredient substitutions — so companies don't need a full new application for every small change.
  • AI tools are already supporting some review work, though decisions remain with agency staff.
  • The backlog is moving: pending applications are down about 70%, and the acceptance-review backlog is down more than 99%.

For pouch makers, this is the most favorable regulatory weather in years. The pilot program already produced the first pouch authorizations explicitly citing lower harmful constituents, and a replacement framework designed around "clarity, predictability, efficiency" could speed decisions for the hundreds of pouch SKUs still waiting — some since the September 2020 deadline.

The pushback has already started

Congressional Democrats aren't waiting. Representative Raja Krishnamoorthi sent a letter to Acting FDA Commissioner Kyle Diamantas on October 6 demanding answers by October 20 — including which specific provisions of the 2021 rule the FDA might change, whether any replacement will lower the scientific evidentiary bar, and whether FDA discussed changes with tobacco manufacturers before announcing the review.

The letter makes the political context explicit: FDA announced its review less than four weeks after Altria subsidiaries NJOY and Helix Innovations — the company behind on! — sued the agency over the PMTA framework on September 2. Critics read the sequence as regulator responding to industry pressure; the FDA frames it as a framework that no longer reflects market realities.

Both things can be true, and neither is settled. The rulemaking hasn't been drafted, the questions have an October 20 deadline, and the current process keeps running meanwhile. But the direction is clear: the FDA that authorized 43 nicotine pouch products now wants a faster, more predictable system — and it has told everyone to watch the pouch pilot to see what that looks like.

Compare nicotine pouch brands and prices across retailers at PouchFinder.

SOURCES: